Immunotherapy Efficacy in Advanced Hepatocellular Carcinoma in a Diverse and Underserved Population in the United States

References

• Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Ca a Cancer J Clinicians. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular Carcinoma. Hepatology. 2021;73 Suppl 1(Suppl1):4–13. doi:10.1002/hep.31288
   PubMed Web of Science ®Google Scholar
• Dongmo CM. Liver Cancer Incidence and Mortality by Year, Bronx County, 1976-2020. State University of New York at Albany; 2022.
   Google Scholar
• Petrick JL, Florio AA, Znaor A, et al. International trends in hepatocellular carcinoma incidence, 1978-2012. Int J Cancer. 2020;147(2):317–330. doi:10.1002/ijc.32723
   PubMed Web of Science ®Google Scholar
• Kamath GR, Taioli E, Egorova N. Liver Cancer Disparities in New York City: a Neighborhood View of Risk and Harm Reduction Factors. Front Oncol. 2018;8.
   PubMed Web of Science ®Google Scholar
• Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 2020;371:m3544. doi:10.1136/bmj.m3544
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervás-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Frenette CT, Isaacson AJ, Bargellini I, Saab S, Singal AG. A Practical Guideline for Hepatocellular Carcinoma Screening in Patients at Risk. Mayo Clinic Proceed Innovat Qual Outcomes. 2019;3(3):302–310. doi:10.1016/j.mayocpiqo.2019.04.005
   PubMedGoogle Scholar
• Makarova-Rusher OV, Altekruse SF, McNeel TS, et al. Population attributable fractions of risk factors for hepatocellular carcinoma in the United States. Cancer. 2016;122(11):1757–1765. doi:10.1002/cncr.29971
   PubMed Web of Science ®Google Scholar
• Singal AG, Yopp A, Skinner S. Utilization of hepatocellular carcinoma surveillance among American patients: a systematic review. J Gen Intern Med. 2012;27(7):861–867. doi:10.1007/s11606-011-1952-x
   PubMed Web of Science ®Google Scholar
• Davila JA, Henderson L, Kramer JR, et al. Utilization of surveillance for hepatocellular carcinoma among hepatitis C virus-infected veterans in the United States. Ann Internal Med. 2011;154(2):85–93. doi:10.7326/0003-4819-154-2-201101180-00006
   PubMed Web of Science ®Google Scholar
• Flores YN, Datta GD, Yang L, et al. Disparities in Hepatocellular Carcinoma Incidence, Stage, and Survival: a Large Population-Based Study. Cancer Epidemiol Biomarkers Prev. 2021;30(6):1193–1199. doi:10.1158/1055-9965.EPI-20-1088
   PubMed Web of Science ®Google Scholar
• Yu JC, Neugut AI, Wang S, et al. Racial and insurance disparities in the receipt of transplant among patients with hepatocellular carcinoma. Cancer. 2010;116(7):1801–1809. doi:10.1002/cncr.24936
   PubMed Web of Science ®Google Scholar
• Dakhoul L, Gawrieh S, Jones KR, et al. Racial Disparities in Liver Transplantation for Hepatocellular Carcinoma Are Not Explained by Differences in Comorbidities, Liver Disease Severity, or Tumor Burden. Hepatol Commun. 2019;3(1):52–62. doi:10.1002/hep4.1277
   PubMed Web of Science ®Google Scholar
• Ha J, Yan M, Aguilar M, et al. Race/Ethnicity-specific Disparities in Hepatocellular Carcinoma Stage at Diagnosis and its Impact on Receipt of Curative Therapies. J Clin Gastroenterol. 2016;50(5):423–430. doi:10.1097/MCG.0000000000000448
   PubMed Web of Science ®Google Scholar
• Mathur AK, Osborne NH, Lynch RJ, Ghaferi AA, Dimick JB, Sonnenday CJ. Racial/ethnic disparities in access to care and survival for patients with early-stage hepatocellular carcinoma. Arch Surg. 2010;145(12):1158–1163. doi:10.1001/archsurg.2010.272
   PubMedGoogle Scholar
• Sobotka LA, Hinton A, Conteh LF. African Americans are less likely to receive curative treatment for hepatocellular carcinoma. World J Hepatol. 2018;10(11):849–855. doi:10.4254/wjh.v10.i11.849
   PubMedGoogle Scholar
• Sonnenday CJ, Dimick JB, Schulick RD, Choti MA. Racial and geographic disparities in the utilization of surgical therapy for hepatocellular carcinoma. J Gastrointest Surg. 2007;11(12):1636–1646. doi:10.1007/s11605-007-0315-8
   PubMed Web of Science ®Google Scholar
• Tan D, Yopp A, Beg MS, Gopal P, Singal AG. Meta-analysis: underutilisation and disparities of treatment among patients with hepatocellular carcinoma in the United States. Aliment Pharmacol Ther. 2013;38(7):703–712. doi:10.1111/apt.12450
   PubMed Web of Science ®Google Scholar
• Ahn JC, Lauzon M, Luu M, et al. Racial and ethnic disparities in early treatment with immunotherapy for advanced HCC in the United States. Hepatology. 2022;76(6):1649–1659. doi:10.1002/hep.32527
   PubMed Web of Science ®Google Scholar
• Cheng A-L, Qin S, Ikeda M, et al. Updated efficacy and safety data from IMbrave150: atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76(4):862–873. doi:10.1016/j.jhep.2021.11.030
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Lau G, Kudo M, et al. Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma. NEJM Evidence. 2022;1(8). doi:10.1056/EVIDoa2100070
   PubMedGoogle Scholar
• Finn RS, Ryoo B-Y, Merle P, et al. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: a Randomized, Double-Blind, Phase III Trial. J Clin Oncol off J Am Soc Clin Oncol. 2020;38(3):193–202. doi:10.1200/JCO.19.01307
   PubMed Web of Science ®Google Scholar
• Yau T, Park J-W, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, Phase 3 trial. Lancet Oncol. 2022;23(1):77–90. doi:10.1016/S1470-2045(21)00604-5
   PubMed Web of Science ®Google Scholar
• Zhu AX, Kang Y-K, Yen C-J, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019;20(2):282–296. doi:10.1016/S1470-2045(18)30937-9
   PubMed Web of Science ®Google Scholar
• De Wilde N, Vonghia L, Francque S, et al. Real-life multi-center retrospective analysis on nivolumab in difficult-to-treat patients with advanced hepatocellular carcinoma. World J Hepatol. 2022;14(8):1608–1620. doi:10.4254/wjh.v14.i8.1608
   PubMed Web of Science ®Google Scholar
• Himmelsbach V, Pinter M, Scheiner B, et al. Efficacy and Safety of Atezolizumab and Bevacizumab in the Real-World Treatment of Advanced Hepatocellular Carcinoma: experience from Four Tertiary Centers. Cancers. 2022;14(7):1722. doi:10.3390/cancers14071722
   PubMed Web of Science ®Google Scholar
• Saeed A, Hildebrand H, Park R, et al. Immune Checkpoint Inhibitors versus VEGF Targeted Therapy as Second Line Regimen in Advanced Hepatocellular Carcinoma (HCC): a Retrospective Study. J Clin Med. 2020;9(9):2682. doi:10.3390/jcm9092682
   PubMed Web of Science ®Google Scholar
• Uhlig J, Stein S, Kim HS. PD-1 targeted immunotherapy for advanced hepatocellular carcinoma: current utilization and outcomes in the USA. Future Oncol. 2022;18(14):1691–1703. doi:10.2217/fon-2021-1487
   PubMed Web of Science ®Google Scholar
• Bien MD, Cedric H, Patel VV, Blackstock OJ, Felsen UR. Reaching Key Populations: prEP Uptake in an Urban Health Care System in the Bronx, New York. AIDS & Behav. 2017;21(5):1309–1314. doi:10.1007/s10461-016-1663-8
   PubMed Web of Science ®Google Scholar
• Ho WJ, Danilova L, Lim SJ, et al. Viral status, immune microenvironment and immunological response to checkpoint inhibitors in hepatocellular carcinoma. J ImmunoTherapy Cancer. 2020;8(1):e000394. doi:10.1136/jitc-2019-000394
   PubMed Web of Science ®Google Scholar
• American Association for the Study of Liver Diseases, Infectious Diseases Society of America. AASLD/IDSA HCV Guidance: recommendations for Testing, Managing, and Treating Hepatitis C. Clin Liver Dis. 2018;12(5):117. doi:10.1002/cld.791
   Google Scholar
• Kumar R, Castillero F, Bhandari S, Malapati S, Kloecker G. The Hispanic paradox in non-small cell lung cancer. Hematology/Oncol Stem Cell Therapy. 2021:9727. doi:10.1016/j.hemonc.2021.02.004
   Google Scholar
• Pinheiro PS, Williams M, Miller EA, Easterday S, Moonie S, Trapido EJ. Cancer survival among Latinos and the Hispanic Paradox. Cancer Causes Control. 2011;22(4):553–561. doi:10.1007/s10552-011-9727-6
   PubMed Web of Science ®Google Scholar